

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Angelucci *et al.*

Application No.: 09/942,137

Group Art Unit: 3732

Filed: August 29, 2001

Examiner: N/A

For: LAMINOPLASTY IMPLANTS AND METHODS OF USE Attorney Docket No.: 8932-538

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.97 AND 1.98



Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 12 2003
TECHNOLOGY CENTER R3700

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of Applicants or Attorneys for Applicants which are or may be related to the patentability of the claimed invention, Attorneys for Applicants hereby direct the Examiner's attention to references AA through AG, which are listed on the accompanying revised PTO Form 1449.

References AA through AF were cited on December 11, 2002 in the PCT Search Report for PCT Application No. PCT/US02/27140. The PCT Search Report is enclosed as reference AG. Note that current references AA and AE were previously disclosed in Applicant's second Information Disclosure Statement as references BB and DZ, respectively. These references are cited in the accompanying revised PTO Form 1449 for completeness. However, new copies of these references are not provided. Copies of references AB through AD, AF and AG are enclosed for the Examiner's convenience.

Identification of the above-listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since that form identifies all of the references cited therein as "Prior

Art.” As an alternative, Applicants submit herewith a “Revised Form PTO 1449” entitled “List of References Cited by Applicant.”

As noted above, references AA and AE were previously disclosed in Applicants’ first and second information disclosure statements. Further, references AB through AD and AF were first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. Accordingly, Applicants estimate that no fee is due. However, should the Patent Office determine that a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date: February 28, 2003



By: Brian M. Rothery

Reg. No. 35,340

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

Enclosures